Dermata is a development-stage biotechnology company founded in late 2014 focused on making major advancements in the treatment of serious diseases treated by dermatologists, with a focus on inflammation and immunology. 

Our business strategy is to identify and develop innovative products that we can quickly move into clinical trials to demonstrate efficacy and safety in a variety of diseases.  We are currently exploring the use of a new chemical entity with a novel drug formulation to deliver drug into the site of the disease for targeted treatment.  With multiple dermatologic diseases being investigated, we have begun to build a strong pipeline that will create significant value for our stockholders.  We believe this strategy will enable us to build a platform of products that we can efficiently move from R&D, through development and into commercialization with an attractive capital return.